Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema)1.0 mg/1.0 mg s.c. once weekly versus tirzepatide

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema)1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in participants with type 2diabetes inadequately controlled on metformin, SGLT2 inhibitor or both

Open

Protocol code: NN9388-7741
EudraCT code: No aplica
Research group: Diabetes and Metabolism
Service: Endocrinology
Principal investigator: Ciudin Mihai, Andreea
Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Phase: Fase III